Efficacy and Safety of Tofacitinib Re-Treatment for Ulcerative Colitis after Treatment Interruption: Results from the OCTAVE Clinical Trials

Julian Panés, Séverine Vermeire, Marla C. Dubinsky, Edward V. Loftus, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Jean Frederic Colombel

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Aims: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. Here, we evaluate the efficacy and safety of tofacitinib re-Treatment following treatment interruption in patients with ulcerative colitis. Methods: Here, patients with clinical response to tofacitinib 10 mg b.d. induction therapy were randomised to receive placebo in OCTAVE Sustain. Those experiencing treatment failure after Week 8 of OCTAVE Sustain entered OCTAVE Open and re-initiated tofacitinib 10 mg b.d. [re-Treatment subpopulation]; efficacy and safety data are presented up to Month 36 of OCTAVE Open. Results: Median time to treatment failure following interruption was 169 (95% confidence interval [CI], 94.0-179.0) and 123 [95% CI, 91.0-168.0] days for induction remitters, and induction responders but non-remitters, respectively. Following re-Treatment with tofacitinib, rates (non-responder imputation after a patient discontinued; latest observation carried forward imputation after a patient advanced to a subsequent study [NRI-LOCF]) of clinical response, remission, and endoscopic improvement were 74.0%, 39.0%, and 55.0% at Month 2, and 48.5%, 37.4%, and 42.4% at Month 36, respectively. Among induction remitters and induction responders but non-remitters, clinical response rates at Month 36 were 60.6% and 42.4% [NRI-LOCF], respectively. Efficacy was recaptured regardless of prior tumour necrosis factor inhibitor failure status. The safety profile of tofacitinib 10 mg b.d. re-Treatment was consistent with the overall cohort and demonstrated no new safety risks associated with exposure of ≤36 months. Conclusions: Median time to treatment failure was numerically higher in induction remitters versus induction responders but non-remitters. Following treatment interruption, efficacy was safely and successfully recaptured with tofacitinib 10 mg b.d. re-Treatment in a substantial proportion of patients [ClinicalTrials.gov:NCT01458574;NCT01470612].

Original languageEnglish (US)
Pages (from-to)1852-1863
Number of pages12
JournalJournal of Crohn's and Colitis
Volume15
Issue number11
DOIs
StatePublished - Nov 1 2021

Keywords

  • Re-Treatment
  • tofacitinib
  • ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Tofacitinib Re-Treatment for Ulcerative Colitis after Treatment Interruption: Results from the OCTAVE Clinical Trials'. Together they form a unique fingerprint.

Cite this